In a report published Wednesday, Deutsche Bank analyst Greg Poole reiterated a Buy rating on Valeant Pharmaceuticals International VRX, and raised the price target from $82.00 to $103.00.
In the report, Deutsche Bank noted, “Maintain Buy Post $8.7B Acquisition of B&L - Which Makes Strategic Sense - We continue to like Valeant's positioning – offering investors one of the few ways to participate in relatively high-growth emerging markets. And we continue to believe it has the potential to generate above-average growth and strong cash flow by leveraging a diverse revenue base, highly efficient tax structure, and robust business development pipeline. And Valeant's announced $8.7B acquisition of global eye care company Bausch & Lomb (B&L) positions VRX to be a global leader in both ophthalmology and dermatology.”
Valeant Pharmaceuticals International closed on Tuesday at $91.80.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in